AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Kairos Pharma, LTD. Director's Dealing 2024

Sep 25, 2024

34903_dirs_2024-09-24_27660473-b31f-4afa-93a5-32c1926d926c.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2024-09-16

Reporting Person: Samuelson Doug (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	58296	Direct